Ligand Pharmaceuticals | LGND - Trade Debtors


Ligand Pharmaceuticals reported $54.8M in Trade Debtors for its fiscal quarter ending in March of 2026.





Trade Debtors Change Date
Agenus USD 22.34M 107K Mar/2026
Amgen USD 10.23B 1.09B Jun/2026
Anika Therapeutics USD 29.33M 661K Dec/2025
Arrowhead Research USD 15.68M 203.19M Mar/2026
Baxter International USD 1.86B 158M Jun/2026
Bristol-Myers Squibb USD 13.83B 535M Jun/2026
Eli Lilly USD 23.48B 2.3B Jun/2026
Enanta Pharmaceuticals USD 40.16M 1.52M Dec/2024
Enviri Corporation USD 341.34M 27.84M Dec/2025
Gilead Sciences USD 5.06B 314M Jun/2026
GlaxoSmithKline GBP 8.07B 137M Jun/2026
Glaxosmithkline GBP 10.49B 40.6M Mar/2026
Heron Therapeutics USD 89.59M 8.54M Dec/2025
Insmed USD 215.32M 36.77M Jun/2026
Intrexon USD 1.02M 559K Jun/2024
Ionis Pharmaceuticals USD 58.84M 15.16M Jun/2026
Karyopharm Therapeutics USD 23.36M 2.82M Mar/2026
Ligand Pharmaceuticals USD 54.8M 6.25M Mar/2026
MacroGenics USD 10.42M 2.95M Mar/2026
Merck USD 12.21B 435M Mar/2026
Pacira USD 132.42M 6.78M Jun/2026
Pfizer USD 16.19B 19M Jun/2026
Rigel Pharmaceuticals USD 28.9M 1.39M Jun/2024
Sangamo BioSciences USD 581K 110K Jun/2024
Veracyte USD 54.18M 4.06M Jun/2026